



# Binary MoS<sub>2</sub> nanostructures as nanocarriers for amplification in multiplexed electrochemical immunosensing: simultaneous determination of B cell activation factor and proliferation-induced signal immunity-related cytokines

Beatriz Arévalo<sup>1</sup> · Marina Blázquez-García<sup>1</sup> · Alejandro Valverde<sup>1</sup> · Verónica Serafín<sup>1</sup> · Ana Montero-Calle<sup>2</sup> · Guillermo Solís-Fernández<sup>2</sup> · Rodrigo Barderas<sup>2</sup> · Susana Campuzano<sup>1</sup> · Paloma Yáñez-Sedeño<sup>1</sup> · José M. Pingarrón<sup>1</sup>

Received: 7 December 2021 / Accepted: 23 February 2022  
© The Author(s) 2022

## Abstract

A dual immunosensor is reported for the simultaneous determination of two important immunity-related cytokines: BAFF (B cell activation factor) and APRIL (a proliferation-induced signal). Sandwich-type immunoassays with specific antibodies (cAbs) and a strategy for signal amplification based on labelling the detection antibodies (dAbs) with binary MoS<sub>2</sub>/MWCNTs nanostructures and using horseradish peroxidase (HRP) were implemented. Amperometric detection was carried out at screen-printed dual carbon electrodes (SPdCEs) through the hydroquinone HQ/H<sub>2</sub>O<sub>2</sub> system. The developed dual immunosensor provided limit of detection (LOD) of 0.08 and 0.06 ng mL<sup>-1</sup> for BAFF and APRIL, respectively, and proved to be useful for the determination of both cytokines in cancer cell lysates and serum samples from patients diagnosed with autoimmune diseases and cancer. The obtained results agreed with those found using ELISA methodologies.

**Keywords** Dual immunoplatfrom · BAFF · APRIL · MoS<sub>2</sub>/MWCNTs · Amperometry · Serum · SLE · CRC

## Introduction

BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) are molecules similar to tumor necrosis factor mainly expressed on B lymphocytes that show structural similarities and interact with three receptors of the TNF family specifically and redundantly: BAFF-R joins BAFF, BCMA joins APRIL and also BAFF with weaker affinity, and TACI joins BAFF and APRIL equally well [1]. Both are type II membrane proteins, and the former is released after being cleaved at the furin protease site as a biologically active and soluble 17 kDa cytokine [2]. APRIL is also

formulated as a membrane-bound protein, which is broken down by furin as a soluble trimeric cytokine [3]. B cells play a pivotal role in autoimmunity not only by producing autoantibodies but also by modulating immune responses via the formation of cytokines and chemokines. The BAFF/APRIL system promotes B cell survival and differentiation, and therefore such cytokines are involved in the pathogenesis of autoimmune diseases. For instance, elevated blood or tissue levels of these biomolecules are frequently observed in patients of systemic lupus erythematosus (SLE) [4], lupus nephritis [5], Sjögren disease [6], or rheumatoid arthritis (RA) [7]. Regarding SLE, BAFF and APRIL serum levels correlate positively with disease activity and other markers, such as the level of serum anti-dsDNA antibodies. In addition, an elevated serum BAFF concentration (equal or greater than 2 ng mL<sup>-1</sup>) predicts the occurrence of moderate to severe SLE flares in patients receiving treatment [4]. On the other hand, increased serum levels of these two cytokines have also been associated with tumor growth and invasion in certain malignancies such as breast cancer [8].

✉ Susana Campuzano  
susanacr@quim.ucm.es

✉ Paloma Yáñez-Sedeño  
yseo@quim.ucm.es

<sup>1</sup> Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain

<sup>2</sup> Chronic Disease Programme, UFIEC, Institute of Health Carlos III, 28220 MajadahondaMadrid, Spain

Despite their importance for monitoring autoimmune diseases which affect large population, no immunosensors for these cytokines have been reported in the literature. Nevertheless, various colorimetric ELISA kits are commercially available for the single determination of BAFF or APRIL. These kits provide logarithmic calibrations over the  $\text{pg mL}^{-1}$  or  $\text{ng mL}^{-1}$  range and require assay times lasting around 4 h. Examples are the Quantikine ELISA Human BAFF/TNFSF13B Immunoassay with a claimed minimum detection dose ( $\text{MDD} = \bar{x} \pm 2s$ ) of  $6.44 \text{ pg mL}^{-1}$  and dynamic range between 62.5 and  $4000 \text{ pg mL}^{-1}$  BAFF, and Human APRIL/TNFSF13 Quantikine ELISA Kit DAPR00 Immunoassay, in the range between 0.2 and  $10 \text{ ng mL}^{-1}$  and  $\text{MDD} = 0.015 \text{ ng mL}^{-1}$  APRIL.

On the other hand, 2D materials, mainly graphene, have been widely used in the last years for technological applications. However, recently, transition metal dichalcogenides (TMDs) have replaced graphene in some applications due to their unique physico-chemical properties. Among TMDs,  $\text{MoS}_2$  is widely used in bioelectronics because of its biocompatibility, semiconductivity, and intrinsic peroxidase-like catalytic activity [9]. Electrochemical biosensors prepared with sheets [10, 11], nanoparticles [12], or  $\text{MoS}_2$  quantum dots [13] have been reported. Furthermore, the poor intrinsic conductivity of  $\text{MoS}_2$  has been improved by preparation of hybrids or composites with carbon nanomaterials to enhance the electron transfer reaction at the interface [14]. Various electrochemical biosensors involving hybrids of  $\text{MoS}_2$  and graphene oxide (GO) [15, 16] or carbon nanotubes (CNTs) [17] have been reported.

In this work,  $\text{MoS}_2$  composite materials with multi-walled carbon nanotubes ( $\text{MoS}_2/\text{MWCNTs}$ ), reduced graphene oxide ( $\text{MoS}_2/\text{rGO}$ ), and a mixture of both nanomaterials ( $\text{MoS}_2/\text{rGO}/\text{MWCNTs}$ ) have been synthesized to select the most appropriate to be used as carrier tag for signal amplification. Characterization of the resulting composite materials and a comparative evaluation of their electrochemical behavior led us to choose  $\text{MoS}_2/\text{MWCNTs}$ , since it exhibited the highest pseudo-peroxidase activity and excellent electrochemical characteristics.

Accordingly, a rapid and highly sensitive dual immunosensor for the simultaneous amperometric determination of BAFF and APRIL at screen-printed dual carbon electrodes (SPdCEs) is presented for the first time in this paper. The specific capture antibodies were covalently immobilized by employing carbodiimide/hydroxysuccinimide chemistry on the surface of the modified working electrodes after electrochemically grafting the diazonium salt of 4-aminobenzoic acid (*p*-ABA), which resulted in covalent binding of the 4-carboxyl phenyl moieties on the carbon surfaces. Sandwich-type immunoassays were implemented using  $\text{MoS}_2/\text{MWCNTs}$ -HRP-dAbs as carrier labels for signal amplification. In these nanocarriers the acid-treated MWCNTs

provided the required functional groups to immobilize a large number of HRP and dAb molecules, and  $\text{MoS}_2$  contributed to improve sensitivity due to its pseudo-peroxidase activity. Amperometric measurements at  $E_{\text{app}} = -0.20 \text{ V}$  vs. Ag pseudo-reference electrode in the presence of  $\text{H}_2\text{O}_2$  and hydroquinone (HQ) were employed to follow the extension of affinity reactions. The developed dual immunosensor successfully tackled the determination of the two target cytokines in cancer cell lysates and serum samples from healthy subjects and patients diagnosed with SLE and colorectal cancer (CRC).

## Experimental

### Reagents, solutions and samples

Multi-walled carbon nanotubes (MWCNTs;  $\phi 30 \pm 15 \text{ nm}$ , 95% purity) were supplied by NanoLab, Brighton, MA. Before use, CNTs were chemically shortened and carboxylated by treatment with nitric and sulfuric acids (v/v 1:3) under ultrasound for 5 h. The resulting product was centrifuged at 4000 rpm for 10 min and washed repeatedly with deionized water up to pH 7 and dried under nitrogen [18]. Graphene oxide (NIT.GO.M.140.10) from NanoInnova Technologies was also used. Ammonium heptamolybdate ( $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4 \text{ H}_2\text{O}$ ), thiourea, N-(3-dimethyl-aminopropyl)-N'-ethylcarbodiimide (EDC), N-hydroxysulfosuccinimide (NHSS), biotin, streptavidin, *p*-aminobenzoic acid (*p*-ABA), sodium nitrite, peroxidase from horseradish (HRP) (Ref. P8250-25KU), streptavidin from *Streptomyces avidinii* (Strep) (Ref. S4762-5MG), hydroquinone (HQ), and hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 30% w/v) were purchased from Sigma-Aldrich. Neutravidin (Neu) was from Thermo Fisher Scientific (Ref. 31,000). Sodium chloride, potassium chloride, sodium di-hydrogen phosphate, di-sodium hydrogen phosphate, and tris-hydroxymethyl-aminomethane-HCl (Tris-HCl) were from Scharlab. Anti-BAFF-biotin capture antibodies ( $\text{b-cAb}_{\text{BAFF}}$ ), anti-BAFF detection antibodies ( $\text{dAb}_{\text{BAFF}}$ ), and human BAFF/BLyS standard were from the Human BAFF/BLyS/TNFSF13B DuoSet ELISA from R&D Systems (Cat. No. DY124-05), and anti-APRIL-biotin capture antibodies ( $\text{cAb}_{\text{APRIL}}$ ), anti-APRIL detection antibodies ( $\text{dAb}_{\text{APRIL}}$ ), and human APRIL standard were from the Human APRIL/TNFSF13 DuoSet ELISA from R&D Systems (Cat. No. DY884B). Biotin was from Gerbu (Lot. 280,611).

Selectivity was checked against human hemoglobin (HB, Cat. No. H7379), albumin from human serum (HSA, Cat. No. A1653), IgG from human serum (hIgG, Ref: I2511), all of them from Sigma-Aldrich, human cadherin-17 from Origene (CDH-17, Ref: TP720740), human neurofilament-L from Cell Signaling Technology® (NfL, Cat. No.

99175), recombinant human tau-441 from BioLegend® (TAU), recombinant human TAR DNA-binding protein 43 from Abcam (TDP-43, Cat. No. ab224788), and human IL-13sR $\alpha$ 2 (Ref: DY614) and human TNF (Ref: DY210) from R&D Systems.

Sera from CRC patients and from healthy individuals were obtained through the IdISSC biobank after approval of the Institutional Ethical Review Boards of the Hospital Clínico San Carlos and the Institute of Health Carlos III, and with the written informed consent of all participating individuals, whereas sera from SLE patients were purchased from Central BioHub. All serum samples were stored at  $-80\text{ }^{\circ}\text{C}$ , until use. All the experiments with these samples were performed accomplishing all the ethical issues and relevant guidelines and regulations of the involved institutions.

SW480 and SW620 (from the American Type Culture Collection (ATCC) cell repository) and KM12C, KM12SM, and KM12L4a (from I. Fidler's laboratory, MD Anderson Cancer Center, Houston, TX) cells were grown and lysed as reported previously [19, 20].

Water purified by the Milli-Q purification system (18.2 M $\Omega$  cm) was used for the preparation of all solutions. The used buffers included B&W buffer pH 7.5 (0.01 mol L $^{-1}$  Tris-HCl pH 7.5 containing 1 mmol L $^{-1}$  EDTA and 2 mmol L $^{-1}$  NaCl), 0.01 mol L $^{-1}$  phosphate buffer saline solution (PBS) pH 7.5, and 0.05 mol L $^{-1}$  phosphate buffer (PB) solution pH 6.0. The solutions used to perform the amperometric detection, 0.1 mol L $^{-1}$  H $_2$ O $_2$  and 0.1 mol L $^{-1}$  HQ, were freshly prepared in phosphate buffer solution pH 6.0.

The 1-Step™ Ultra TMB-ELISA Substrate Solution from Thermo Scientific™ (Cat. No. 34028) was also used.

## Apparatus and electrodes

All the amperometric measurements were made at room temperature using a CHI812B (CH Instruments, Inc.) potentiostat controlled by the CHI812B software. A  $\mu$ Autolab type III potentiostat (Ecochemie) controlled by FRA2 software electrochemical impedance spectroscopy (EIS) was employed for other electrochemical measurements.

Screen-printed carbon electrodes (SPCEs, DRP-110), with a 4 mm- $\varnothing$  carbon working electrode, and dual SPCEs (DRP-X1110) consisted of two elliptic carbon working electrodes with a surface area of 5.6 mm $^2$  were from Metrohm-DropSens. These electrodes include a carbon counter electrode and an Ag pseudo-reference electrode. The specific cable connectors (DRP-CAC and DRP-BICAC) used as interface between the SPCEs and dual SPCEs, respectively, and the potentiostat were also from Metrohm-DropSens. The measurements were made in stirred solutions using 10-mL glass electrochemical cells from Pobel. A Crison model Basic 20 + pH meter, a P-Selecta Ultrasons ultrasonic bath, a Heidolph Reax Top homogenizer for small samples, and an

MPW-65R centrifuge from MPW (Med. Instruments) were also employed. Scanning electron microscopy (SEM) was made with a JEOM 7600 electron microscope operating at 5 kV. The transmission electron microscopy (TEM) characterization was performed using a JEM 2100 PLUS microscope operating at 100 kV. Raman analysis was performed in a NT-MDT NTEGRA Spectra spectrometer, equipped with a Solar TII MS5004i monochromator and an Andor iDUS DU-420 CCD detector. The excitation source is a laser of 532-nm wavelength and 22 mW. ELISA absorbance readings were made in a Sunrise™ Tecan microplate reader with the Magellan V 7.1 software.

## Procedures

### Preparation of MoS $_2$ /MWCNTs

The MoS $_2$ /MWCNTs composite was prepared by the hydrothermal route [21, 22]: 2.5 mg carboxylated MWCNTs (c-MWCNTs) suspended in 20 mL deionized water were ultrasonically stirred for 30 min to obtain a homogeneous dispersion. Then, 33 mg of ammonium heptamolybdate ((NH $_4$ ) $_6$ Mo $_7$ O $_{24}$ ·4 H $_2$ O) and 60 mg thiourea were added and, after stirring for 30 min at 800 rpm, the resulting solution was transferred to a Teflon-lined stainless-steel reactor and kept into an oven at 200  $^{\circ}\text{C}$  for 24 h. Once cooling down to room temperature (60 min approximately), the black precipitate was collected by centrifugation, washed three times with 10 mL ethanol, other three times with 10 mL water, and dried during 24 h at 37  $^{\circ}\text{C}$ . For comparison purposes, MoS $_2$ , MoS $_2$ /rGO, and MoS $_2$ /rGO/MWCNTs were also prepared by applying similar procedures to that described above with no carbon nanomaterials, with 3.0 mg GO, or with 3.0 mg GO plus 2.5 mg c-MWCNTs, respectively.

Stock solutions containing 1 mg mL $^{-1}$  MoS $_2$ /MWCNTs were prepared by suspending the product in 10 mM PBS of pH 7.5 and stirring ultrasonically to obtain a homogeneous dispersion. Similarly, solutions from the other MoS $_2$ -based materials were prepared. The resulting dispersions were stored at room temperature in the dark.

### Preparation of MoS $_2$ /MWCNTs(-HRP)-dAbs

MoS $_2$ /MWCNTs(-HRP)-dAbs carrier tags were prepared through a similar protocol to that reported previously for the preparation of other nanocarriers involving MWCNTs hybrids [18, 23, 24]. Briefly, 500  $\mu$ L of 0.1 mg mL $^{-1}$  MoS $_2$ /MWCNTs was centrifuged at 14,000 rpm during 10 min and the remaining product was incubated in the darkness under continuous stirring for 6 h at room temperature with 200  $\mu$ L of a 400 mM EDC and 100 mM NHSS mixture solution prepared in 100 mM PBS pH 7.4. The resulting

solution was centrifuged at 14,000 rpm during 5 min and the product washed three times with 10 mM PBS pH 7.4. Activated MoS<sub>2</sub>/MWCNTs were conjugated during 24 h at 4 °C under continuous stirring with a mixture solution prepared in 100 mM PBS pH 7.4 containing 10 mg mL<sup>-1</sup> HRP and 6 μg mL<sup>-1</sup> dAb<sub>BAFF</sub> to prepare MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>BAFF</sub> conjugates. A similar procedure was used with 10 mg mL<sup>-1</sup> HRP and 5 μg mL<sup>-1</sup> dAb<sub>APRIL</sub> to prepare MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>APRIL</sub> labels. The as-prepared carriers were centrifuged at 14,000 rpm during 5 min, washed three times with 10 mM PBS pH 7.4, re-suspended in 500 μL of 100 mM PBST pH 7.4, and stored at 4 °C until their use.


### Preparation of the electrochemical scaffold

The scheme depicted in Fig. 1 shows how both single and dual SPCEs were functionalized by reductive electrochemical grafting with *p*-ABA following the protocol reported previously [25] with slight modifications. In a first step, diazonium salt was prepared by adding dropwise 2 mM NaNO<sub>2</sub> aqueous solution to a 1 mg mL<sup>-1</sup> *p*-ABA solution prepared in 1 M HCl and cooling with ice (38 mL NaNO<sub>2</sub>

for each 2 mL *p*-ABA solution). The reaction was allowed proceeding for 7 min under stirring. Thereafter, each electrode was immersed into the diazonium salt solution and ten successive voltammetric cycles over the 0 to -1.0 V range ( $\nu = 200 \text{ mV s}^{-1}$  vs. the Ag pseudo-reference electrode) were scanned. Finally, the modified SPCEs were washed thoroughly with Milli-Q water and dried at room temperature.

### Preparation of the immunosensors

The carboxylic groups of grafted SPCEs were activated by dropping 10 μL of a fresh 100 mM each EDC and NHSS mixture solution in 25 mM MES buffer of pH 5.0 on the working electrode surfaces and left to react for 30 min. After washing with the 25 mM MES buffer of pH 5.0, 3 μL of a 600 or 400 μg mL<sup>-1</sup> Neu solution prepared in the same MES buffer was placed onto the SPdCE working electrodes for the preparation of BAFF and APRIL immunosensors, respectively, allowing incubation for 30 min. The electrode was rinsed with 10 mM PBS pH 7.4 and, subsequently, the biotinylated capture antibodies (cAb<sub>BAFF</sub> or cAb<sub>APRIL</sub>) were immobilized by adding 3 μL of 100 ng mL<sup>-1</sup> or 5 μg mL<sup>-1</sup>,



**Fig. 1** Schematic display of the different steps involved in the preparation of the MWCNTs/MoS<sub>2</sub>(-HRP)-dAb nanocarriers (a) and of the dual immunosensor constructed for the determination of BAFF and APRIL biomarkers using amperometric transduction (b)

respectively, prepared in 10 mM PBS pH 7.4 and incubating for 30 min. Then, a blocking step was carried out by adding 10  $\mu\text{L}$  of a 2 mg  $\text{mL}^{-1}$  biotin solution prepared in the same PBS and incubated during 15 min. After washing with BB, 3  $\mu\text{L}$  of the APRIL or BAFF standard solutions or the samples prepared in BB solution were placed onto each working electrode and incubated for 30 min. After rinsing with BB, 3  $\mu\text{L}$  of the  $\text{MoS}_2/\text{MWCNTs}(-\text{HRP})\text{-dAb}$  bioconjugate suspension were dropped onto the electrode surface and incubated for 30 min. The resulting immunosensing platform was washed again with 10 mM PBS pH 7.4 and kept with a 25  $\mu\text{L}$  drop of the same buffer until the electrochemical measurements were made. All incubation steps involved in the immunosensor fabrication were performed at room temperature in a humid environment to prevent drop evaporation.

### Amperometric measurements

The amperometric measurements were carried out by immersing the modified electrode into the measuring cell containing 10 mL of 50 mM PB pH 6.0 and 100  $\mu\text{L}$  of a fresh solution of 100 mM HQ prepared in the same buffer. The measurements were carried out under stirring by applying  $-0.20$  V vs. the Ag pseudo-reference electrode. Once the background current was stabilized ( $\sim 50$  s), 50  $\mu\text{L}$  of a 100 mM  $\text{H}_2\text{O}_2$  solution prepared daily in 50 mM PB pH 6.0 were added and the variation in the cathodic current

due to the HRP reduction of  $\text{H}_2\text{O}_2$  mediated by HQ, reaching the steady state in  $\sim 100$  s, was recorded. The analytical responses given through the text correspond to the difference between the steady state and the background currents. They are the mean values of three replicates, and the error bars displayed were estimated as three times the standard deviation of each set of replicates ( $\alpha = 0.05$ ).

Figure 1 shows a scheme of the steps involved in the preparation of the dual immunosensor as well as the reactions occurring in the amperometric detection.


### Statistical analysis

ROC analysis was performed using GraphPad Prism 9 ROC curve analysis functionality using Wilson/Brown method and a 95% confidence interval, and R (Version 4.1.1) using “Epi” and “ModelGood” packages.

## Results and discussion

### Characterization of $\text{MoS}_2$ hybrids

The morphology of  $\text{MoS}_2$  hybrids was characterized by scanning electron microscopy (SEM). Figure 2 shows some representative images of the bare nanomaterials (Fig. 2a–c),  $\text{MoS}_2/\text{MWCNTs}$  (Fig. 2d),  $\text{MoS}_2/\text{rGO}/\text{MWCNTs}$  (Fig. 2e),



**Fig. 2** SEM images of (a)  $\text{MoS}_2$  (inset at higher magnification), (b) o-MWCNTs, (c) GO (inset at higher magnification), (d)  $\text{MoS}_2/\text{MWCNTs}$ , (e)  $\text{MoS}_2/\text{rGO}/\text{MWCNTs}$ , and (f)  $\text{MoS}_2/\text{GO}$


and MoS<sub>2</sub>/rGO (Fig. 2f) nanocomposites. Figure 2a displays two SEM images at different magnification levels of MoS<sub>2</sub> obtained through the hydrothermal synthesis showing the formation of aggregates consisting of many sheets tightly stacked together [26]. MoS<sub>2</sub>/MWCNTs (Fig. 2d) shows a two-dimensional structure of carbon nanotubes (see Fig. 2b) with some decorating nanoparticles, presumably MoS<sub>2</sub>. Interconnections between MoS<sub>2</sub> nanoparticles through carbon nanotubes and the high porosity suggest a good electrochemical behavior for this material. Regarding MoS<sub>2</sub>/rGO/MWCNTs (Fig. 2e), the SEM image shows a large amount of MoS<sub>2</sub> nanoaggregates deposited onto the three-dimensional network formed by carbon nanomaterials [22]. However, when this morphology is compared with that of MoS<sub>2</sub>/rGO (Fig. 2f), a quite different structure is observed since MoS<sub>2</sub> nanoparticles grew in a laminar way on the rGO sheets (see Fig. 2c), with no globular nanostructures, thus making difficult to distinguish between both materials. In summary, MoS<sub>2</sub> composites prepared with carbon nanotubes mostly maintain the bare material structure providing rough surface morphology in the form of nanoaggregates, while in the presence of GO, the synthesized MoS<sub>2</sub> appears as well-dispersed sheets on rGO substrate.

Transmission electron microscopy (TEM) was also used to investigate the structure of MoS<sub>2</sub> nanocomposites. As Fig. 3 shows, bare MoS<sub>2</sub> appears in the form of aggregated layers, this structure being preserved in the MoS<sub>2</sub>/MWCNTs nanocomposite, where some nanotubes can also be



observed (Fig. 3b). In the MoS<sub>2</sub>/rGO composite (Fig. 3c), MoS<sub>2</sub> nanosheets appear scattered onto rGO sheets. It has been reported that MoS<sub>2</sub>/rGO composites could acquire a 3D architecture caused by self-assembling during the hydrothermal process, in which reduction of GO can drive to partial overlapping or coalescing of the sheets [27]. Furthermore, a more complex structure showing MoS<sub>2</sub> aggregates and some carbon nanotubes onto the rGO can be observed for MoS<sub>2</sub>/rGO/MWCNTs (Fig. 3d).

Figure 4 compares the vibrational Raman spectra of MWCNTs, MoS<sub>2</sub>/MWCNTs, and MoS<sub>2</sub>/rGO/MWCNTs nanocomposites at a  $\lambda_{\text{exc}}$  of 532 nm. As can be seen, the spectra of the MoS<sub>2</sub>/MWCNTs and MoS<sub>2</sub>/rGO/MWCNTs nanomaterials displayed the vibration peak characteristic of MoS<sub>2</sub>: the E<sub>2g</sub><sup>1</sup>, due to the in-plane opposing motions of S and Mo atoms, and the A<sub>1g</sub> peak, which represents the out-of-plane relative motion of S atoms [28]. Moreover, a higher frequency shift was observed in the D and G bands of the MoS<sub>2</sub>/rGO/MWCNTs spectrum compared to that of MoS<sub>2</sub>/MWCNTs, indicating a substantial interaction between the MWCNTs, MoS<sub>2</sub>, and the rGO layers [29]. In addition, the peaks associated with LA(M), E<sub>1g</sub>, E<sub>2g</sub><sup>1</sup>, and A<sub>1g</sub> modes of MoS<sub>2</sub>, shifted from 267, 295, 392, and 431 cm<sup>-1</sup> in the MoS<sub>2</sub>/MWCNTs to 264, 292, 387, and 430 cm<sup>-1</sup> for the MoS<sub>2</sub>/rGO/MWCNTs. The band observed at 359 cm<sup>-1</sup> in both MoS<sub>2</sub> nanocomposites should be associated with O–Mo–O bending modes of bridging oxygen in MoO<sub>3</sub> [30]. Furthermore, G, D, and D' bands have been

**Fig. 3** TEM images of: **a** MoS<sub>2</sub>, **b** MoS<sub>2</sub>/MWCNTs (inset: o-MWCNTs), **c** MoS<sub>2</sub>/GO (inset: GO), and **d** MoS<sub>2</sub>/rGO/MWCNTs



**Fig. 4** (a) Raman spectra and (b) zoom at high frequencies of MWCNTs (black), MoS<sub>2</sub>/MWCNTs (red), and MoS<sub>2</sub>/rGO/MWCNTs (blue) nanocomposites at  $\lambda_{\text{exc}} = 532$  nm




**Fig. 5** UV spectra of (1) GO, (2) o-MWCNTs, (3) MoS<sub>2</sub>, (4) MoS<sub>2</sub>/rGO, (5) MoS<sub>2</sub>/MWCNTs, and (6) MoS<sub>2</sub>/rGO/MWCNTs

previously reported and attributed to defects in the processed MWCNTs [21].

UV–Vis spectroscopy was used to verify the formation of MoS<sub>2</sub> hybrids (Fig. 5). Absorbance spectra from aqueous dispersions of the synthesized nanocomposites

(30  $\mu\text{g mL}^{-1}$ ) and the bare nanomaterials were recorded. No bands appeared in the range of scanned wavelengths for rGO (curve 1) or MWCNTs (curve 2). However, the MoS<sub>2</sub> spectrum (curve 3) showed two absorption bands at 210 and 230 nm that also appeared in the MoS<sub>2</sub>/MWCNTs (curve 5) and MoS<sub>2</sub>/rGO/MWCNTs (curve 6) spectra. However, these bands are much poorly defined in the MoS<sub>2</sub>/rGO spectrum (curve 4) probably due to an encapsulation effect of MoS<sub>2</sub> by rGO [16].

In order to evaluate the peroxidase-like catalytic activity of the MoS<sub>2</sub>-based nanomaterials, the TMB/H<sub>2</sub>O<sub>2</sub> system was employed as substrate. Figure 6 shows as the colorless solution developed a clearly and almost immediate visible blue color corresponding to the oxidized TMB in the presence of MoS<sub>2</sub>/MWCNTs. The blue color is due to the formation of a radical in the decomposition of hydrogen peroxide, which acts as an oxidant [31]. This same behavior was observed using other peroxidase substrates, OPD (o-phenylenediamine) and ABTS. These results show the higher ability of MoS<sub>2</sub> to exhibit its intrinsic properties in composites prepared without rGO, due to the absence of encapsulation that occurs in the presence of flat graphene sheets [16]



**Fig. 6** Photographs showing the peroxidase activity of MoS<sub>2</sub> nanocomposites in 250  $\mu\text{L}$  of the TMB/H<sub>2</sub>O<sub>2</sub> ready to use commercial solution

## Electrochemical characterization of MoS<sub>2</sub> nanomaterials

SPCEs were modified by dropping 5  $\mu\text{L}$  of the as-prepared dispersions of MoS<sub>2</sub> nanomaterials onto the working electrode surfaces and allowing drying. Then, cyclic voltammograms (CVs) and electrochemical impedance spectra (EIS) from 5 mM [Fe(CN)<sub>6</sub>]<sup>3-/4-</sup> in 0.1 M KCl solutions were recorded (Fig. 7). As it can be seen, no significant voltammetric differences were apparent for all the electrodes, with similar anodic and cathodic  $i_p$ ,  $E_p$ , and  $\Delta E$  values in the electroactivity range of the redox probe. However, Nyquist spectra exhibited significantly lower electron transfer resistance ( $R_{CT}$ ) values for the electrodes modified with carbon nanotubes/MoS<sub>2</sub> hybrids (MoS<sub>2</sub>/MWCNTs and MoS<sub>2</sub>/rGO/MWCNTs). This behavior can be attributed to a better conductivity of these composites due to the presence of carbon nanotubes, since such behavior was not observed for the electrode modified with MoS<sub>2</sub> and rGO. Probably, as SEM and TEM images suggested, the carbon nanotube hybrids possess a more porous nanostructure that increases the specific surface of the electrode providing more active sites for target molecules. The larger differences observed using EIS compared with CV are probably due to the different rationale and mode of application of the two techniques. Whereas cyclic voltammetry involves large potential perturbations, in EIS the system is only infinitesimally perturbed with respect to the steady state.


## Optimization of the experimental variables involved in the preparation of the dual immunosensor

According to the scheme depicted in Fig. 1, the SPdCE was functionalized by electrografting with *p*-ABA, and the modified electrodes (*p*-ABA/SPdCE) were activated with EDC/NHSS for the covalent immobilization of Neu (Neu-Phe-SPdCE). Then, the biotinylated capture antibodies, cAb<sub>BAFF</sub>

and cAb<sub>APRIL</sub>, were immobilized on the respective working electrode and a sandwich configuration for each biomarker was implemented with MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>BAFF</sub> or MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>APRIL</sub> carrier tags.

The effect of the experimental variables involved in the preparation of MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>BAFF</sub> (or -dAb<sub>APRIL</sub>) carrier tags and the cAb<sub>BAFF</sub>-Neu-Phe-SPdCE (or cAb<sub>APRIL</sub>-) bioelectrodes, on the amperometric responses provided by the resulting MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>BAFF</sub>-BAFF-cAb<sub>BAFF</sub>-Neu-Phe-SPdCE or MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>APRIL</sub>-APRIL-cAb<sub>APRIL</sub>-Neu-Phe-SPdCE, was evaluated. Larger ratio between the currents measured with the as-prepared immunosensors in the presence (S) of 5 ng mL<sup>-1</sup> or 4 ng mL<sup>-1</sup> BAFF or APRIL standards, respectively, or in the absence (B) of the target compounds was taken as the selection criterion for each tested variable. The optimization studies implied the evaluation of (a) MoS<sub>2</sub>/MWCNTs(-HRP)-dAb<sub>BAFF</sub> (or -dAb<sub>APRIL</sub>) loadings, and those of dAb<sub>BAFF</sub> (or dAb<sub>APRIL</sub>) and HRP onto the MoS<sub>2</sub>/MWCNTs nanocomposite; (b) selection between Strep or Neu binding protein immobilized onto Phe-SPdCEs; (c) loading and incubation time of Neu onto Phe-SPdCEs; (d) concentration and incubation time of biotinylated capture antibodies (cAbs) onto Neu-Phe-SPdCEs; (e) type, concentration, and incubation time of the blocking agent; (f) incubation time of BAFF or APRIL cytokines onto cAb-Neu-Phe-SPdCEs; and (g) incubation time of the corresponding nanocarrier tag onto BAFF-cAb<sub>BAFF</sub>-Neu-Phe-SPdCE or APRIL-cAb<sub>APRIL</sub>-Neu-Phe-SPdCE. The results of these studies are shown in the Supplementary Material (Figs. S1–S5) and summarized in Table 1. Moreover, the experimental conditions used for the modification of SPdCEs by grafting from the electrochemically generated *p*-ABA cation radical were the same as optimized previously [32]. The detection potential of -0.20 V vs. Ag pseudo-reference electrode was also previously selected for the same catalytic system [33].

**Fig. 7** Cyclic voltammograms (a) and Nyquist plots (b) recorded for 5 mM [Fe(CN)<sub>6</sub>]<sup>3-/4-</sup> in 0.1 M KCl solutions for (1) bare SPCE, (2) MoS<sub>2</sub>/SPCE, (3) MoS<sub>2</sub>/GO/SPCE, (4) MoS<sub>2</sub>/MWCNTs/SPCE, and (5) MoS<sub>2</sub>/GO/MWCNTs/SPCE. **a**  $\nu = 50 \text{ mV s}^{-1}$  and **b** range of frequencies: 10<sup>5</sup>–0.04 Hz; open circuit. The equivalent circuits used to adjust the experimental results are shown below



**Table 1** Optimization of the experimental variables affecting the preparation and functioning of the dual immunosensor developed for the simultaneous determination of BAFF and APRIL cytokines

Variable	BAFF		APRIL	
	Tested range	Selected value	Tested range	Selected value
MWCNTs/MoS <sub>2</sub> loading, mg mL <sup>-1</sup>	0.05–0.4	0.1	0.05–0.4	0.2
dAb loading, µg mL <sup>-1</sup>	0–9	6	0–20	5
HRP loading, mg mL <sup>-1</sup>	0.25–2	1	0.5–3	1
Affinity	Strep or Neu	Neu	Strep or Neu	Neu
Neutravidin loading, µg mL <sup>-1</sup>	0–800	600	0–800	400
Neutravidin incubation time, min	15–60	15	15–60	30
cAb, ng mL <sup>-1</sup> (BAFF); µg mL <sup>-1</sup> (APRIL)	0–500	100	0–10	5
cAb incubation time, min	15–60	30	5–60	15
Blocking mixture*	A–D	D	A–D	D
Biotin loading, mg mL <sup>-1</sup>	1–5	2	1–5	2
Biotin incubation time, min	15–60	15	15–60	15
Target protein incubation time, min	15–60	30	15–60	30
MoS <sub>2</sub> /MWCNTs(-HRP)-dAb incubation time, min	15–60	30	10–60	15

\* (A) 2 mg mL<sup>-1</sup> biotin, (B) 2% casein + 2 mg mL<sup>-1</sup> biotin, (C) 2% BSA, and (D) 2% casein + 1% BSA + 3 mg mL<sup>-1</sup> biotin.

## Electrochemical characterization of the immunosensors


The stepwise immunosensors' preparation were monitored by EIS using 5 mM Fe(CN)<sub>6</sub><sup>4-/3-</sup> as redox probe. Figures S6a-d shows representative Nyquist plots and the equivalent circuits for the modified SPCE and the corresponding immunosensors. As can be seen, after modification of the SPCE with *p*-ABA there was a large increase in the electron transfer resistance,  $R_{CT}$ , from 972 to 3862 Ω (Fig. S6a) because of electrostatic repulsion between the anionic redox probe and the surface-confined –COO<sup>-</sup> groups of the modified electrode surface at the measuring pH. On the contrary, there was a drastic decrease in the  $R_{CT}$  value (not shown) after activation with EDC/NHSS due to the neutralization of these –COO<sup>-</sup> groups. Then, the  $R_{CT}$  value remained relatively low after immobilization of Neu protein (2015 Ω and 1809 Ω, green curves in Figs. S6a and c, respectively). The impedance spectra corresponding to the immobilization of the immunoreagents are displayed in Figure S6b and d. As expected, an increase in the electron transfer resistance occurred upon immobilization of the biotinylated capture antibodies (cAb<sub>BAFF</sub> or cAb<sub>APRIL</sub>), with  $R_{CT}$  values of 2196 Ω (BAFF) and 2076 Ω (APRIL), due to the resistance to electron transfer produced by the partially insulating layer created by these biomolecules on the electrode surface. In the case of the BAFF immunosensor (blue curve in Fig. S6b), the Nyquist diagram is somewhat distorted, while two semicircles are clearly observed in the APRIL spectrum (blue curve in Fig. S6d). This behavior can be attributed to the existence of two distinct layers on the surface of the electrode which is more evident in the case

of APRIL because of the larger concentration of capture antibody (5 µg mL<sup>-1</sup> vs. 100 ng mL<sup>-1</sup>). In both cases, the resistance increased after incubation with the antigen solutions (brown curves in Figs. S6c and d) because of hindered interfacial electron transfer by the immobilized proteins, with  $R_{CT}$  values of 2326 Ω (BAFF) and 2368 Ω (APRIL). However, a remarkable decrease was observed upon incubation with the MoS<sub>2</sub>/MWCNTs(-HRP)-dAb nanocarrier tag (purple curves in Figs. S6c and d), with  $R_{CT(BAFF)} = 2225$  Ω and  $R_{CT(APRIL)} = 2187$ , which is most likely due to the higher conductivity of the resulting surface.

The obtained Nyquist plots can be defined by two different equivalent circuits as shown in Figure S6. The spectra of Figures S6a and c fitted well with the R1(C2[R3W1]) circuit, whereas the spectra in Figures S6b and d should be explained by a more complex scheme with at least two RC semi-circuits. The  $R_{CT2}$  value, corresponding to the second semicircle of the Nyquist plot, represented the electron transfer across the immobilized substances including biotinylated capture antibodies, the antigens, and the MoS<sub>2</sub>/MWCNTs(-HRP)-dAb nanocarrier tag.

## Analytical characteristics for the simultaneous determination of BAFF and APRIL

Figure 8 shows the calibration plots obtained with the dual immunosensor for BAFF and APRIL standard solutions. The relationships between currents ( $\Delta i$ ) and the logarithm of the biomarker concentration provide linear ranges from 0.24 to 120 ng mL<sup>-1</sup> ( $r^2 = 0.999$ ) (BAFF) and 0.19 to 25 ng mL<sup>-1</sup> ( $r^2 = 0.997$ ) (APRIL), fitting the equations:  $\Delta i, \text{ nA} = (244 \pm 3) \log [\text{BAFF, ng mL}^{-1}] + (487 \pm 3)$



**Fig. 8** Calibration plots constructed with the dual immunosensor for BAFF (white points) and APRIL (black points) using MoS<sub>2</sub>/MWCNTs(-HRP)-dAb as carrier tags for the amperometric measurements at  $-0.20$  V vs. Ag pseudo-reference electrode. Other working conditions are summarized in Table 1

and  $\Delta i, \text{nA} = (258 \pm 5) \log [\text{APRIL}, \text{ng mL}^{-1}] + (389 \pm 4)$ . These calibration data were compared with those obtained by constructing calibrations using MWCNTs(-HRP)-dAb, i.e., without MoS<sub>2</sub> incorporated to the carbon nanotubes, or HRP-IgG-dAb, i.e., without MoS<sub>2</sub> and MWCNTs.

In the first case, remarkably lower slope values,  $86 \pm 7$  nA per decade of concentration (BAFF) and  $179 \pm 8$  nA per decade of concentration (APRIL), were found over the same dynamic ranges with  $r^2 = 0.991$  and  $0.993$ , respectively. The higher sensitivity achieved with the bioplatfroms constructed with carrier tags involving MoS<sub>2</sub> nanoparticles highlights their favorable contribution to enhance conductivity and their intrinsic pseudo-peroxidase activity that reinforces that of HRP. Furthermore, in absence of MoS<sub>2</sub> and carbon nanotubes, the slope values are even lower,  $39 \pm 3$  nA per decade of concentration (BAFF) ( $r^2 = 0.990$ ) and  $140 \pm 6$  nA per decade of concentration (APRIL) ( $r^2 = 0.994$ ), due to the loss of the large specific surface area provided by carbon nanotubes to immobilize large amounts of detection antibodies, HRP, and MoS<sub>2</sub> nanoparticles, and to promote fast and efficient electron transfer.

Limit of detection, LOD ( $0.08 \text{ ng mL}^{-1}$  BAFF and  $0.06 \text{ ng mL}^{-1}$  APRIL), and limit of quantification, LQ ( $0.26 \text{ ng mL}^{-1}$  BAFF and  $0.19 \text{ ng mL}^{-1}$  APRIL) values, were calculated according to the  $3 s_b/m$  and  $10 s_b/m$  criteria, where  $s_b$  was estimated as the standard deviation for ten amperometric measurements without target protein and  $m$  was the slope of the corresponding standard calibration plot (Fig. 8). The reproducibility of the measurements

provided by the immunoplatfroms was assessed by comparing the amperometric signals provided for  $10 \text{ ng mL}^{-1}$  of BAFF or  $2.5 \text{ ng mL}^{-1}$  of APRIL standards with 5 different immunosensors prepared in the same manner on both the same day (relative standard deviation, RSD, values of 2.9 and 2.4%, respectively) and different days (RSD of 3.6 and 3.3%, respectively). These results confirm the good reproducibility of the protocols involved both in the preparation of the immunosensors and in the amperometric measurements.

These analytical characteristics are compared with those claimed for the commercial ELISA kits. The kits that use the same immunoreagents (see “Experimental” section) provide logarithmic calibration plots with linear ranges from  $39.1$  to  $2500 \text{ pg mL}^{-1}$  BAFF and from  $31.2$  to  $2000 \text{ pg mL}^{-1}$  APRIL. Although these ranges start from lower concentrations, the immunoplatfroms cover larger ranges. In addition, the kit protocols do not inform about the detection limits or precision levels. Other kits from the same company (see “Introduction” section) provide linear ranges between  $62.5$  and  $4000 \text{ pg mL}^{-1}$  BAFF with a minimum detection dose ( $\text{MDD} = \bar{x} \pm 2s$ ) of  $6.44 \text{ pg mL}^{-1}$ , and between  $0.2$  and  $10 \text{ ng mL}^{-1}$  APRIL with  $\text{MDD} = 0.015 \text{ ng mL}^{-1}$ . RSD values range between 3.4 and 11.6% (BAFF) and 3.8 and 8.5% (APRIL) for intra-assays and inter-assays, respectively. All these immunoassays require 4 h 30 min to be implemented. Therefore, it is worth highlighting the lower RSD values obtained with the dual immunosensor, as well as the shorter assay time. Indeed, the method reported in this paper allows the simultaneous determination of both cytokines in approximately 1 h 30 min counting since the cAbs were immobilized (similarly to that reported for the ELISA methods) onto the SPdCEs, i.e., in a three times shorter assay time than that required for the single determination of one biomarker by ELISA. In addition, the achieved sensitivities for both cytokines are perfectly adequate for the analysis of clinical samples where the expected concentrations are in the  $\text{ng mL}^{-1}$  range. So, levels in serum of healthy patients of  $0.8 \text{ ng mL}^{-1}$  BAFF [34] and  $4 \text{ ng mL}^{-1}$  APRIL [35] have been reported.

In addition, the stability of both immunoplatfroms ( $\text{cAb}_{\text{BAFF/APRIL}}\text{-Neu-Phe-SPdCE}$ , stored in a humid chamber) and bionanoconjugates (MWCNTs/MoS<sub>2</sub>-(-HRP)-dAb<sub>BAFF/APRIL</sub> resuspended in PBST) stored after their preparation at  $4^\circ\text{C}$  was assessed by comparing the amperometric responses they provided in the absence and presence of BAFF ( $10 \text{ ng mL}^{-1}$ ) or APRIL ( $4 \text{ ng mL}^{-1}$ ) standards. According to these studies, the prepared bionanoconjugates were stable for at least 3 months (Figure S7a) and the immunoplatfroms during 33 days (Fig. 7Sb), providing during these periods amperometric responses included within the limits of control set at  $\pm 3$  times the standard deviation of three measurements performed on the day of their preparation (day 0).

### Selectivity

The selectivity of the dual immunoplatfrom was checked by comparison of the currents measured for 0- and 10-ng mL<sup>-1</sup> BAFF or 0- and 4-ng mL<sup>-1</sup> APRIL standards, in absence or in the presence of various non-target proteins coexisting in serum as well as other biomarkers for autoimmune diseases and cancer at the concentration they found in healthy individuals. The results displayed in Fig. 9 proved that there were no significant differences in the S/B ratios for all proteins tested, falling in all cases within the range of  $\pm 3 \times$  standard deviation of the current measured in the absence of interferent (the corresponding  $\Delta i$  values, in nA, are given in Table S1 of the Supplementary Information).

The possible cross-talking between the two close bioelectrodes, WE1 (BAFF immunosensing surface) and WE2 (APRIL immunosensing surface), at the dual SPCE was evaluated. Figure S8 in the Supplementary Information compares the amperometric currents measured with the dual immunosensor in solutions containing varying concentrations of BAFF and APRIL standards, ensuring the absence of cross-talking between immunosensing surfaces due to the presence of the non-target cytokine.

### Application to the analysis of cancer cell lysates and serum samples

The developed immunosensors were applied to the analysis of the two target cytokines in CRC cell lysates with different metastatic potential and in serum samples from healthy individuals and from patients diagnosed with SLE and CRC.


Table S2 in the Supplementary Information shows a statistical comparison of the slope values of the calibration plots constructed for both analytes using standards prepared in the different matrices. As it can be seen, no apparent matrix effect was found for the determination of the two biomarkers for ten-fold diluted serum samples and 0.5  $\mu$ g of cell extract.

Accordingly, the determination of both cytokines in the different analyzed samples was carried out simply by interpolation of the amperometric responses provided by the immunosensors in the calibration plots constructed with standard solutions of the cytokines (Fig. 8). The results obtained as well as those provided by the ELISA methodologies for the single determination of each cytokine are summarized in Table 2.

The obtained results revealed a higher expression of BAFF and APRIL in cells with higher metastatic potential (KM12SM, KM12L4a, and SW620), in agreement with the role played by these cytokines in the tumorigenesis and metastasis of CRC [36–38].

Similarly, the results obtained in serum samples demonstrate the significantly higher expression of both cytokines in patients with SLE and CRC compared to healthy individuals. Figure 10 displays the results by patient group showing that it is possible to clearly discriminate patients with these important pathologies from healthy individuals by interrogating these cytokines. It is important to note that, in general, the serum level of APRIL is larger than that of BAFF in the three groups of analyzed patients.

The obtained results agree with those reported in the literature on the hyperexpression of these cytokines for SLE [39–42] and CRC [37, 43–46] patients.



**Fig. 9** Amperometric responses measured with the dual immunosensor for 0- (white bar) and 10-ng mL<sup>-1</sup> BAFF or 4-ng mL<sup>-1</sup> APRIL (grey bar) standards prepared in absence and in the presence of 1 mg mL<sup>-1</sup> hIgG, 50 mg mL<sup>-1</sup> HSA, 5 mg mL<sup>-1</sup> BSA, 5 mg mL<sup>-1</sup>

HB, 30 pg mL<sup>-1</sup> NfL, 5 pg mL<sup>-1</sup> TAU, 1 ng mL<sup>-1</sup> TDP-43, 500 ng mL<sup>-1</sup> CDH-17, 10 ng mL<sup>-1</sup> IL13Rα2, 100 pg mL<sup>-1</sup> TNFα, 4 ng mL<sup>-1</sup> APRIL, or 1 ng mL<sup>-1</sup> BAFF

**Table 2** Concentrations of BAFF and APRIL (in ng mL<sup>-1</sup>) determined using the developed dual immunosensors and the ELISA methods for their single determination in cell extracts and serum samples

Sample	Cell/individual	BAFF			APRIL		
		Immunosensor*	ELISA*	$t_{\text{exp}}^{**}$	Immunosensor*	ELISA*	$t_{\text{exp}}^{**}$
Cell extracts	KM12C	1.7 ± 0.1; 2.5	1.9 ± 0.3; 5.4	0.314	1.7 ± 0.1; 3.0	1.7 ± 0.3; 6.1	0.001
	KM12SM	5.00 ± 0.03; 2.4	5.3 ± 0.6; 4.8	0.348	7.0 ± 0.6; 3.4	8 ± 1; 7.5	0.828
	KM12L4a	3.2 ± 0.2; 2.0	3.1 ± 0.3; 4.5	0.070	4.5 ± 0.4; 3.5	4.2 ± 0.5; 4.6	0.324
	SW480	0.90 ± 0.07; 3.2	1.1 ± 0.2; 8.0	0.275	0.81 ± 0.05; 2.4	0.8 ± 0.1; 5.1	0.043
	SW620	2.6 ± 0.2; 2.5	2.8 ± 0.4; 6.1	0.309	3.1 ± 0.2; 2.9	3.4 ± 0.5; 6.2	0.385
Serum	Healthy	0.45 ± 0.05; 3.6	0.49 ± 0.09; 7.1	0.057	2.2 ± 0.1; 2.1	2.2 ± 0.2; 3.5	0.026
		0.29 ± 0.03; 3.8	0.29 ± 0.05; 6.9	0.011	1.70 ± 0.08; 1.9	1.7 ± 0.2; 4.5	0.051
		0.32 ± 0.03; 3.5	0.34 ± 0.04; 5.2	0.004	2.2 ± 0.2; 1.5	2.2 ± 0.3; 5.3	0.050
		0.22 ± 0.02; 3.8	0.23 ± 0.04; 7.7	0.005	1.70 ± 0.06; 1.4	1.6 ± 0.3; 7.3	0.149
		0.37 ± 0.04; 4.8	0.39 ± 0.05; 5.0	0.027	1.9 ± 0.2; 3.6	2.2 ± 0.3; 5.3	0.395
		0.14 ± 0.05; 2.8	0.12 ± 0.02; 7.0	0.015	1.8 ± 0.1; 3.3	1.8 ± 0.3; 6.4	0.007
		0.26 ± 0.02; 3.6	0.30 ± 0.06; 7.9	0.043	2.0 ± 0.2; 3.6	1.9 ± 0.3; 6.1	0.052
	0.57 ± 0.07; 4.8	0.7 ± 0.1; 6.2	0.110	1.6 ± 0.2; 4.5	1.6 ± 0.3; 7.4	0.162	
	SLE	1.9 ± 0.2; 4.4	1.9 ± 0.3; 5.6	0.027	6.7 ± 0.4; 2.3	7.2 ± 0.8; 4.4	0.573
		1.20 ± 0.09; 3.1	1.2 ± 0.2; 5.9	0.065	6.4 ± 0.5; 3.2	6 ± 1; 6.6	1.021
		2.0 ± 0.1; 2.8	2.1 ± 0.3; 6.0	0.125	7.0 ± 0.3; 1.8	6 ± 1; 6.8	0.703
	CRC	1.4 ± 0.1; 3.5	1.4 ± 0.2; 6.6	0.012	7.0 ± 0.3; 2.0	6.3 ± 0.6; 3.9	0.893
		3.1 ± 0.2; 5.0	3.6 ± 0.6; 6.4	0.652	7.5 ± 0.6; 3.2	7.3 ± 0.7; 3.7	0.233
		4.3 ± 0.8; 3.1	4.2 ± 0.7; 6.6	0.044	7.8 ± 0.6; 3.4	8.2 ± 0.6; 3.0	0.449
		2.9 ± 0.2; 3.3	3.1 ± 0.5; 6.0	0.321	4.8 ± 0.3; 2.2	4.8 ± 0.5; 4.0	0.002
4.5 ± 0.4; 3.3		4.9 ± 0.6; 4.8	0.518	8.1 ± 0.7; 3.6	7.9 ± 0.7; 3.4	0.148	


\*Mean value ±  $t \times s / \sqrt{n}$ ; RSD, %,  $n=3$ ,  $\alpha=0.05$ .

\*\* $t_{\text{exp}} < t_{\text{tab}}$  of 4.303 ( $n=3$ ,  $\alpha=0.05$ ).


In addition, the BAFF concentrations found agree with those reported by other authors for SLE patients and healthy individuals ( $1.47 \pm 1.54$  vs.  $0.517 \pm 0.18$  ng mL<sup>-1</sup> [40]) and ( $3.19 \pm 4.26$  vs.  $0.97 \pm 0.21$  ng mL<sup>-1</sup> [41]) as well as with the cut-off value established at 1429.4 pg mL<sup>-1</sup> [42].

The statistical analysis of the results provided by the developed immunoplatfroms against those obtained by the ELISA methods for the single determination of both cytokines showed an excellent correlation (Fig. 11), thus confirming the accuracy of the results provided by the dual immunosensor.

**Fig. 10** BAFF (a) and APRIL (b) concentrations determined with the dual immunosensors for serum samples grouped into pools of healthy individuals and SLE and CRC patients. Real amperograms obtained for representative serum samples of a healthy individual and patients diagnosed with SLE and CRC are displayed



**Fig. 11** Correlation plots between the BAFF (a) and APRIL (b) concentrations determined with the developed dual immunosensors and the ELISA methodologies for both the analyzed cellular lysates and serum samples. The three replicates made for each sample are included in the plots



To further deepen in the potential of the developed bioplatfroms for diagnosing patients with SLE and CRC by amperometric determination of the two target cytokines, and to establish the best cut-off values that allow reliably discriminating between the three groups of patients analyzed, the results obtained were plotted on the ROC curves shown in Figure S9. According to them for the comparison between healthy individuals and SLE or CRC patients the area under the curve was 100%. When comparing SLE patients to healthy, a maximum cut-off with 100% specificity and 100% sensitivity was achieved for a concentration of BAFF equal to 0.885 ng mL<sup>-1</sup>. Similarly, CRC patients versus healthy individual comparison had a best cut-off with 100% specificity and also 100% sensitivity for 1.735 ng mL<sup>-1</sup>. Finally, for the comparison of SLE versus CRC patients, maximum sensitivity and specificity, 100% for both, were achieved at a cut-off of 2.45 ng mL<sup>-1</sup> of BAFF.

In the case of APRIL, equivalent 100% sensitivity and specificity were achieved for the comparison of SLE and CRC patients against the healthy individuals for 4.3 ng mL<sup>-1</sup> and 3.5 ng mL<sup>-1</sup>, respectively. However, no significant differences could be found between SLE and CRC patient APRIL levels.

## Conclusions

This work reports the first bioplatfroms for the simultaneous determination of BAFF and APRIL, two relatively newly described cytokines of great relevance in autoimmune and cancer diseases. The immunoplatfrom, implemented in an integrated format, involved the use of *p*-aminobenzoic acid-grafted, screen-printed carbon electrodes to allow the efficient immobilization of the capture antibodies, and the use of MWCNTs decorated with MoS<sub>2</sub> nanoparticles as nanocarriers of the detector antibodies and HRP to carry out the electrochemical signal amplification. An amperometric transduction at -0.20 V (vs. Ag pseudo-reference electrode)

using SPdCE in the presence of the hydroquinone/H<sub>2</sub>O<sub>2</sub> system allowed an excellent sensitivity (LOD values of 0.08 and 0.06 ng mL<sup>-1</sup> for BAFF and APRIL, respectively) to be achieved as well as a great selectivity, and operational and storage stability (cAb<sub>BAFF/APRIL</sub>-Neu-Phe-SPdCE ≥ 30 days; MWCNTs/MoS<sub>2</sub>-(HRP)-dAb<sub>BAFF/APRIL</sub> ≥ 100 days). The dual immunoplatfrom allowed the accurate determination of both target cytokines in cancer cell lysates (0.5 μg/determination) and serum samples (10 times diluted) of patients diagnosed with SLE and CRC without matrix effect. These pioneering results demonstrate the potential of these dual immune platfroms as well as their competitiveness against commercially available ELISA methodologies for the single determination of the target biomarkers, to be easily transferable to the clinic for their simplicity, affordable cost, reduced assay time, and point-of-care and multiplexed operation. These results open a new avenue to assist in the management of these patients and to further investigate the role played by these cytokines in these or other prevalent diseases.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00604-022-05250-4>.

**Author contribution** Beatriz Arévalo: methodology, investigation, writing — review and editing — original draft. Marina Blázquez: methodology, investigation, review and editing — original draft. Alejandro Valverde: methodology, investigation, review and editing — original draft. Verónica Serafin: methodology, investigation, writing — review and editing — original draft. Ana Montero-Calle: investigation, resources, review and editing original draft. Guillermo Solís-Fernández: investigation, resources, review and editing original draft. Rodrigo Barderas: conceptualization, supervision, resources, review and editing original draft, funding acquisition. Susana Campuzano: conceptualization, supervision, resources, writing, review and editing original draft, funding acquisition. Paloma Yáñez-Sedeño: conceptualization, supervision, resources, writing, review and editing original draft, funding acquisition. José M. Pingarrón: supervision, resources, review and editing original draft.

**Funding** Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Financial support was provided by Spanish Ministerio de Ciencia, Innovacion y Universidades (RTI2018-096,135-B-I00), Spanish Ministerio de Ciencia e Innovación

(PID2019-103899RB-I00) Research Project, and the TRANSNA-NOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349). Financial support of the PI17CIII/00045 and PI20CIII/00019 grants from the AES-ISCI program was also provided to R. B. A predoctoral contract from the Spanish Ministerio de Ciencia, Innovación y Universidades (PRE2019-087,596) was provided to B. Arévalo. A FPU predoctoral contract supported by the Spanish Ministerio de Educación, Cultura y Deporte was provided to A. M.-C. G. S.-F. is recipient of a predoctoral contract (grant number 1193818 N) supported by The Flanders Research Foundation (FWO).

## Declarations

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. *Semin Immunol* 18:263–275
- Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF and APRIL: a tutorial on B cell survival. *Annu Rev Immunol* 21:231
- Kimberley FC, Hahne M, Medema JP (2009) APRIL hath put a spring of youth in everything. Relevance of APRIL for survival. *J Cell Physiol* 218:1
- Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF/APRIL system in SLE pathogenesis. *Nat Rev Rheumatol* 10:365
- Kang SA, Fedoriw Y, Brennehan EK, Truong YK, Kikly K, Vilen BJ (2017) BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. *J Immunol* 198:2602
- Varin M-M, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers J-O (2010) B-cell tolerance breakdown in Sjögren's syndrome: Focus on BAFF. *Autoimmun Rev* 9:604
- Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M (2019) The role of BAFF and APRIL in rheumatoid arthritis. *J Cell Physiol* 234:17050
- Pelekanou V, Notas G, Athanasouli P, Alexakis K, Kiagiadaki F, Peroulis N, Kalyvianaki K, Kampouri E, Polioudaki H, Theodoropoulos P, Tsapis A, Castanas E, Kampa M (2018) BCMA (TNFRSF17) induces APRIL and BAFF mediated breast cancer cell stemness. *Front Oncol* 8:301
- Zadeh KK, Ou J (2016) Biosensors based on two-dimensional MoS<sub>2</sub>. *ACS Sensors* 1:5–16
- Ganatra R, Zhang Q (2014) Few-layer MoS<sub>2</sub>: a promising layered semiconductor. *ACS Nano* 8:4074
- Dalila RN, Arshad MK, Gopinath SCB, Norhaimi WMW, Fathil MFM (2019) Current and future envision on developing biosensors aided by 2D molybdenum disulfide (MoS<sub>2</sub>) productions. *Biosens Bioelectron* 132:248
- Wang T, Zhu H, Zhuo J, Zhu Z, Papakonstantinou P, Lubarsky G, Lin J, Li M (2013) Biosensor based on ultrasized MoS<sub>2</sub> nanoparticles for electrochemical detection of H<sub>2</sub>O<sub>2</sub> released by cells at the nanomolar level. *Anal Chem* 85:10289–10295
- Lin D, Su Z, Wei G (2018) Three-dimensional porous reduced graphene oxide decorated with MoS<sub>2</sub> quantum dots for electrochemical determination of hydrogen peroxide. *Mater Today Chem* 7:76
- Kudr J, Adam V, Zitka O (2019) Fabrication of graphene/molybdenum disulfide composites and their usage as actuators for electrochemical sensors and biosensors. *Molecules* 24:3374
- Venkatesan A, Rathi S, Lee IY, Park J, Lim D, Kang M, Joh HI, Kim GH, Kannan ES (2017) Molybdenum disulfide nanoparticles decorated reduced graphene oxide: highly sensitive and selective hydrogen sensor. *Nanotechnol* 28:365501
- Yoon J, Lee T, Bharate BG, Jo J, Oh B-K, Choi J-W (2017) Electrochemical H<sub>2</sub>O<sub>2</sub> biosensor composed of myoglobin on MoS<sub>2</sub> nanoparticle-graphene oxide hybrid structure. *Biosens Bioelectron* 93:14
- Lin Y, Chen X, Lin Y, Zhou Q, Tang D (2015) Non-enzymatic sensing of hydrogen peroxide using a glassy carbon electrode modified with a nanocomposite made from carbon nanotubes and molybdenum disulfide. *Microchim Acta* 182:1803
- Serafín V, Valverde A, Martínez-García G, Martínez-Periñán E, Comba F, Garranzo-Asensio M, Barderas R, Yáñez-Sedeño P, Campuzano S, Pingarrón JM (2019) Graphene quantum dots-functionalized multi-walled carbon nanotubes as nanocarriers in electrochemical immunosensing. Determination of IL-13 receptor  $\alpha 2$  in colorectal cells and tumor tissues with different metastatic potential. *Sens Actuators B Chem* 284:711–722
- Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Pedrero M, Farchado M, Vargas E, Manuel de Villena FJ, Garranzo-Asensio M, Barderas R, Pingarrón JM (2017) Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates. *PLoS One* 12:e0175056
- Valverde A, Povedano E, Ruiz-Valdepeñas Montiel V, Yáñez-Sedeño P, Garranzo-Asensio M, Barderas R, Campuzano S, Pingarrón JM (2018) Electrochemical immunosensor for IL-13 receptor  $\alpha 2$  determination and discrimination of metastatic colon cancer cells. *Biosens Bioelectron* 117:766–772
- Koroteev VO, Bulusheva LG, Asanov IP, Shlyakhova EV, Vyalykh DV, Okotrub AV (2011) Charge transfer in the MoS<sub>2</sub>/carbon nanotube composite. *J Phys Chem C* 115:21199
- Govindasamy M, Mani V, Chen S-M, Karthik R, Manibalan K, Umamaheswari R (2016) MoS<sub>2</sub> flowers grown on graphene/carbon nanotubes: a versatile substrate for electrochemical determination of hydrogen peroxide. *Int J Electrochem Sci* 11:2954
- Sánchez-Tirado E, González-Cortés A, Yáñez-Sedeño P, Pingarrón JM (2018) Magnetic multiwalled carbon nanotubes as nanocarrier tags for sensitive determination of fetuin in saliva. *Biosens Bioelectron* 113:88–94
- Valverde A, Serafín V, Montero-Calle A, González-Cortés A, Barderas R, Yáñez-Sedeño P, Campuzano S, Pingarrón JM (2020) Carbon/inorganic hybrid nanoarchitecture as carrier for signaling in electrochemical immunosensors. First biosensor for inflammatory and metastatic processes biomarker RANK-ligand. *ChemElectroChem* 7:810–820
- Martínez-García G, Agüí L, Yáñez-Sedeño P, Pingarrón JM (2016) Multiplexed electrochemical immunosensing of obesity-related hormones at grafted graphene-modified electrodes. *Electrochim Acta* 202:209–215
- Xing LW, Ma ZF (2016) A glassy carbon electrode modified with a nanocomposite consisting of MoS<sub>2</sub> and reduced graphene oxide

- for electrochemical simultaneous determination of ascorbic acid, dopamine, and uric acid. *Microchim Acta* 183:257–263
27. Song H, Tang A, Xu G, Liu L, Yin M, Pan Y (2018) One-step convenient hydrothermal synthesis of MoS<sub>2</sub>/rGO as a high-performance anode for sodium-ion batteries. *Int J Electrochem Sci* 13:4720–4730
  28. Shen P, Yang X, Du M, Zhang H (2021) Temperature and laser-power dependent Raman spectra of MoS<sub>2</sub>/rGO hybrid and few-layered MoS<sub>2</sub>. *Physica B* 604:412693
  29. Basu AK, Sah AN, Pradhan A, Bhattacharya S (2019) Poly-L-lysine functionalized MWCNT-rGO nanosheets based 3-d hybrid structure for femtomolar level cholesterol detection using cantilever based sensing platform. *Sci Rep* 9:3686
  30. Singh S, Sharma S (2021) MoS<sub>2</sub>/multiwalled carbon nanotubes based composite for room-temperature ammonia sensing. *Proc in press, Mater Today*. <https://doi.org/10.1016/j.matpr.2021.01.364>
  31. Zheng J, Song D, Chen H, Xua J, Alharbi NS, Hayat T, Zhang M (2020) Enhanced peroxidase-like activity of hierarchical MoS<sub>2</sub>-decorated N-doped carbon nanotubes with synergetic effect for colorimetric detection of H<sub>2</sub>O<sub>2</sub> and ascorbic acid. *Chinese Chem Lett* 31:1109
  32. Ojeda I, Lopez-Montero J, Moreno-Guzmán M, Janegitz BC, González-Cortés A, Yáñez-Sedeño P, Pingarrón JM (2012) Electrochemical immunosensor for rapid and sensitive determination of estradiol. *Anal Chim Acta* 743:117–124
  33. Eguílaz M, Moreno-Guzmán M, Campuzano S, González-Cortés A, Yáñez-Sedeño P, Pingarrón JM (2010) An electrochemical immunosensor for testosterone using functionalized magnetic beads and screen-printed carbon electrodes. *Biosens Bioelectron* 26:517–522
  34. Kryštůfková O, Hulejová H, Mann HF, Pecha O, Pütová I, Ekholm L, Lundberg IE, Vencovský J (2018) Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis. *Arthritis Res Ther* 20:158
  35. Treamtrakranpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-ong S, Leelahavanichkul A, Hirankarn N, Avihingsanon Y (2012) APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. *Arthritis Res Ther* 14:R252
  36. Lascano V, Zabalegui LF, Cameron K, Guadagnoli M, Jansen M, Burggraaf M, Versloot M, Rodermond H, van der Loos C, Carvalho-Pinto CE, Kalthoff H, Medema JP, Hahne M (2012) The TNF family member APRIL promotes colorectal tumorigenesis. *Cell Death Differ* 19:1826–1835
  37. Wang G, Wang F, Ding W, Wang J, Jing R, Li H, Wang X, Wang Y, Ju S, Wang H (2013) APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. *PLoS ONE* 8(1): e55298
  38. Warakomska M, Tynecka M, Lemancewicz D, Grubczak K, Dzieciol J, Moniuszko M, Eljaszewicz A, Bolkun L (2021) The effects of BAFF and APRIL signaling on non-small cell lung cancer cell proliferation and invasiveness. *Oncol Lett* 22(4):728
  39. Stohl W, Metyas S, Tan S-M, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus. *Arthritis Rheum* 48(12):3475–3486
  40. Fawzy SM, Gheita TA, El-Nabarawy E, El-Demellawy HH, Shaker OG (2011) Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus. *Egypt Rheumatol* 33:45–51
  41. Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Muñoz-Valle JF, Orozco-López M, Marín-Rosales M, Palafox-Sánchez CA (2015) Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. *Lupus* 0:1–11.
  42. Vasconcellos A, Marken J, Wang T, Lood C, Giltiay NV (2017) Increased levels of BAFF in SLE patients correlates with neutrophil activation and autoantibody production [abstract]. *Arthritis Rheumatol* 69 (suppl 10). <https://acrabstracts.org/abstract/increased-levels-of-baff-in-sle-patients-correlates-with-neutrophil-activation-and-autoantibody-production/>. Accessed July 11, 2021.
  43. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmeler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. *J Exp Med* 188:1185–1190
  44. Moreaux J, Veyrune J-L, De Vos J, Klein B (2019) APRIL is overexpressed in cancer: link with tumor progression. *BMC Cancer* 9:83
  45. Calu V, Ionescu A, Stanca L, Geicu OI, Iordache F, Pisoschi AM, Serban AI, Bilteanu L (2021) Key biomarkers within the colorectal cancer related inflammatory microenvironment. *Sci Rep* 11:7940
  46. Kampa M, Notas G, Stathopoulos EN, Tsapis A, Castanas E (2020) The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer. *Front Oncol* 10:827

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.